Loading…
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association be...
Saved in:
| Published in: | International journal of molecular sciences 2019-02, Vol.20 (4), p.824 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3 |
| container_end_page | |
| container_issue | 4 |
| container_start_page | 824 |
| container_title | International journal of molecular sciences |
| container_volume | 20 |
| creator | Pawelczyk, Konrad Piotrowska, Aleksandra Ciesielska, Urszula Jablonska, Karolina Gletzel-Plucinska, Natalia Grzegrzolka, Jedrzej Podhorska-Okolow, Marzenna Dziegiel, Piotr Nowinska, Katarzyna |
| description | The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1.
866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of
(
) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR).
PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (
< 0.0001) and in higher lymph node status (pN) (
= 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (
= 0.0332) in adenocarcinoma (AC) only.
PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group. |
| doi_str_mv | 10.3390/ijms20040824 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8338b924b9374626b4ab2ef2a5c59662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8338b924b9374626b4ab2ef2a5c59662</doaj_id><sourcerecordid>2332042929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3</originalsourceid><addsrcrecordid>eNpdkktv1DAURiMEog_YsUaW2LAg4HfiDVKVtlBpgIqWteVXMh4Se7AzqPwTfi6eTltN2diWfe7R9dVXVa8QfE-IgB_8asoYQgpbTJ9Uh4hiXEPIm6d754PqKOcVhJhgJp5XBwQ2XLQMH1Z_v8fRgdiDy9N6gcDZzTq5nH0MwAfwNYb6alLjCDpXlsUmDKBTwbgEVLDgeul8ApcpDiHm2Rtw5Yfge2-2CFDGxGR9KZkj6EYfvIlrNS_jGIeCjOBcmTmmfKs69epe8kWlny7lF9WzXo3Zvbzbj6sf52fX3ed68e3TRXeyqA1t2rm2jeWQQ4soQQhTKzhRUFvYCqUh5w3tnWaa90YxzoTjriecWdZzqwXRvSPH1cXOa6NayXXyk0p_ZFRe3l7ENEiVSl-jky0hrRaYlsqGcsw1VRq7HitmmOAcF9fHnWu90ZOzxoU5qfGR9PFL8Es5xN-SU0QQ4UXw9k6Q4q-Ny7OcfDZl9iq4uMkSY4ga1DZMFPTNf-gqblIoo5KYEAwpFnhLvdtRJsWck-sfmkFQbuMj9-NT8Nf7H3iA7_NC_gF0IcHi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2332042929</pqid></control><display><type>article</type><title>Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Pawelczyk, Konrad ; Piotrowska, Aleksandra ; Ciesielska, Urszula ; Jablonska, Karolina ; Gletzel-Plucinska, Natalia ; Grzegrzolka, Jedrzej ; Podhorska-Okolow, Marzenna ; Dziegiel, Piotr ; Nowinska, Katarzyna</creator><creatorcontrib>Pawelczyk, Konrad ; Piotrowska, Aleksandra ; Ciesielska, Urszula ; Jablonska, Karolina ; Gletzel-Plucinska, Natalia ; Grzegrzolka, Jedrzej ; Podhorska-Okolow, Marzenna ; Dziegiel, Piotr ; Nowinska, Katarzyna</creatorcontrib><description>The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1.
866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of
(
) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR).
PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (
< 0.0001) and in higher lymph node status (pN) (
= 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (
= 0.0332) in adenocarcinoma (AC) only.
PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20040824</identifier><identifier>PMID: 30769852</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Apoptosis ; Breast ; Colon ; Diagnostic systems ; Fatalities ; Immunoglobulins ; Immunotherapy ; Ki-67 ; Ligands ; Lung cancer ; Lymphatic system ; Lymphocytes ; Medical prognosis ; Metastasis ; Necrosis ; non-small cell lung cancer ; Non-small cell lung carcinoma ; p63 ; PD-L1 ; PD-L1 protein ; Prostate ; Prostate cancer ; Protein expression ; Proteins ; T cell receptors ; TTF-1</subject><ispartof>International journal of molecular sciences, 2019-02, Vol.20 (4), p.824</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3</citedby><cites>FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3</cites><orcidid>0000-0001-8275-7266 ; 0000-0001-6901-1240 ; 0000-0002-7989-3264 ; 0000-0003-4093-7386 ; 0000-0001-8316-8893</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2332042929/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2332042929?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30769852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pawelczyk, Konrad</creatorcontrib><creatorcontrib>Piotrowska, Aleksandra</creatorcontrib><creatorcontrib>Ciesielska, Urszula</creatorcontrib><creatorcontrib>Jablonska, Karolina</creatorcontrib><creatorcontrib>Gletzel-Plucinska, Natalia</creatorcontrib><creatorcontrib>Grzegrzolka, Jedrzej</creatorcontrib><creatorcontrib>Podhorska-Okolow, Marzenna</creatorcontrib><creatorcontrib>Dziegiel, Piotr</creatorcontrib><creatorcontrib>Nowinska, Katarzyna</creatorcontrib><title>Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1.
866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of
(
) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR).
PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (
< 0.0001) and in higher lymph node status (pN) (
= 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (
= 0.0332) in adenocarcinoma (AC) only.
PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.</description><subject>Antigens</subject><subject>Apoptosis</subject><subject>Breast</subject><subject>Colon</subject><subject>Diagnostic systems</subject><subject>Fatalities</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Ki-67</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Necrosis</subject><subject>non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>p63</subject><subject>PD-L1</subject><subject>PD-L1 protein</subject><subject>Prostate</subject><subject>Prostate cancer</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>T cell receptors</subject><subject>TTF-1</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkktv1DAURiMEog_YsUaW2LAg4HfiDVKVtlBpgIqWteVXMh4Se7AzqPwTfi6eTltN2diWfe7R9dVXVa8QfE-IgB_8asoYQgpbTJ9Uh4hiXEPIm6d754PqKOcVhJhgJp5XBwQ2XLQMH1Z_v8fRgdiDy9N6gcDZzTq5nH0MwAfwNYb6alLjCDpXlsUmDKBTwbgEVLDgeul8ApcpDiHm2Rtw5Yfge2-2CFDGxGR9KZkj6EYfvIlrNS_jGIeCjOBcmTmmfKs69epe8kWlny7lF9WzXo3Zvbzbj6sf52fX3ed68e3TRXeyqA1t2rm2jeWQQ4soQQhTKzhRUFvYCqUh5w3tnWaa90YxzoTjriecWdZzqwXRvSPH1cXOa6NayXXyk0p_ZFRe3l7ENEiVSl-jky0hrRaYlsqGcsw1VRq7HitmmOAcF9fHnWu90ZOzxoU5qfGR9PFL8Es5xN-SU0QQ4UXw9k6Q4q-Ny7OcfDZl9iq4uMkSY4ga1DZMFPTNf-gqblIoo5KYEAwpFnhLvdtRJsWck-sfmkFQbuMj9-NT8Nf7H3iA7_NC_gF0IcHi</recordid><startdate>20190214</startdate><enddate>20190214</enddate><creator>Pawelczyk, Konrad</creator><creator>Piotrowska, Aleksandra</creator><creator>Ciesielska, Urszula</creator><creator>Jablonska, Karolina</creator><creator>Gletzel-Plucinska, Natalia</creator><creator>Grzegrzolka, Jedrzej</creator><creator>Podhorska-Okolow, Marzenna</creator><creator>Dziegiel, Piotr</creator><creator>Nowinska, Katarzyna</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8275-7266</orcidid><orcidid>https://orcid.org/0000-0001-6901-1240</orcidid><orcidid>https://orcid.org/0000-0002-7989-3264</orcidid><orcidid>https://orcid.org/0000-0003-4093-7386</orcidid><orcidid>https://orcid.org/0000-0001-8316-8893</orcidid></search><sort><creationdate>20190214</creationdate><title>Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers</title><author>Pawelczyk, Konrad ; Piotrowska, Aleksandra ; Ciesielska, Urszula ; Jablonska, Karolina ; Gletzel-Plucinska, Natalia ; Grzegrzolka, Jedrzej ; Podhorska-Okolow, Marzenna ; Dziegiel, Piotr ; Nowinska, Katarzyna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antigens</topic><topic>Apoptosis</topic><topic>Breast</topic><topic>Colon</topic><topic>Diagnostic systems</topic><topic>Fatalities</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Ki-67</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Necrosis</topic><topic>non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>p63</topic><topic>PD-L1</topic><topic>PD-L1 protein</topic><topic>Prostate</topic><topic>Prostate cancer</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>T cell receptors</topic><topic>TTF-1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pawelczyk, Konrad</creatorcontrib><creatorcontrib>Piotrowska, Aleksandra</creatorcontrib><creatorcontrib>Ciesielska, Urszula</creatorcontrib><creatorcontrib>Jablonska, Karolina</creatorcontrib><creatorcontrib>Gletzel-Plucinska, Natalia</creatorcontrib><creatorcontrib>Grzegrzolka, Jedrzej</creatorcontrib><creatorcontrib>Podhorska-Okolow, Marzenna</creatorcontrib><creatorcontrib>Dziegiel, Piotr</creatorcontrib><creatorcontrib>Nowinska, Katarzyna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pawelczyk, Konrad</au><au>Piotrowska, Aleksandra</au><au>Ciesielska, Urszula</au><au>Jablonska, Karolina</au><au>Gletzel-Plucinska, Natalia</au><au>Grzegrzolka, Jedrzej</au><au>Podhorska-Okolow, Marzenna</au><au>Dziegiel, Piotr</au><au>Nowinska, Katarzyna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-02-14</date><risdate>2019</risdate><volume>20</volume><issue>4</issue><spage>824</spage><pages>824-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1.
866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of
(
) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR).
PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (
< 0.0001) and in higher lymph node status (pN) (
= 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (
= 0.0332) in adenocarcinoma (AC) only.
PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30769852</pmid><doi>10.3390/ijms20040824</doi><orcidid>https://orcid.org/0000-0001-8275-7266</orcidid><orcidid>https://orcid.org/0000-0001-6901-1240</orcidid><orcidid>https://orcid.org/0000-0002-7989-3264</orcidid><orcidid>https://orcid.org/0000-0003-4093-7386</orcidid><orcidid>https://orcid.org/0000-0001-8316-8893</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2019-02, Vol.20 (4), p.824 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_8338b924b9374626b4ab2ef2a5c59662 |
| source | Open Access: PubMed Central; Publicly Available Content Database |
| subjects | Antigens Apoptosis Breast Colon Diagnostic systems Fatalities Immunoglobulins Immunotherapy Ki-67 Ligands Lung cancer Lymphatic system Lymphocytes Medical prognosis Metastasis Necrosis non-small cell lung cancer Non-small cell lung carcinoma p63 PD-L1 PD-L1 protein Prostate Prostate cancer Protein expression Proteins T cell receptors TTF-1 |
| title | Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A09%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20PD-L1%20Expression%20in%20Non-Small%20Cell%20Lung%20Cancer%20and%20Their%20Prognostic%20Significance%20according%20to%20Clinicopathological%20Factors%20and%20Diagnostic%20Markers&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Pawelczyk,%20Konrad&rft.date=2019-02-14&rft.volume=20&rft.issue=4&rft.spage=824&rft.pages=824-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20040824&rft_dat=%3Cproquest_doaj_%3E2332042929%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-d7d6060d1431124d963a0bd089ab06674feb5b6fca5659e6ef365d5f6db93bfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2332042929&rft_id=info:pmid/30769852&rfr_iscdi=true |